Nuo Therapeutics Financials
This page shows Nuo Therapeutics (AURX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rapid revenue scaling is shrinking the loss ratio, but cash still depends on outside financing and a thinner liquidity buffer.
From FY2023 to FY2025, revenue climbed more than fivefold to$3.3M , while operating loss stayed near-$2.5M ; that pattern says added volume is mainly soaking up fixed overhead rather than creating earnings. The more revealing signal is cash burn improved faster than reported losses: operating cash flow was-$865K despite a-$2.5M net loss, implying part of the business is being financed through working-capital timing and accrued obligations rather than from internally generated cash.
By FY2025, negative equity of
Gross margin compressed to
Financial Health Signals
We are recalculating Nuo Therapeutics's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Nuo Therapeutics scores -19.07, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($46.5M) relative to total liabilities ($2.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nuo Therapeutics passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Nuo Therapeutics generates $0.34 in operating cash flow (-$865K OCF vs -$2.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Nuo Therapeutics generated $3.3M in revenue in fiscal year 2025. This represents an increase of 142.7% from the prior year.
Nuo Therapeutics's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.1% from the prior year.
Nuo Therapeutics reported -$2.5M in net income in fiscal year 2025. This represents a decrease of 8.1% from the prior year.
Cash & Balance Sheet
Nuo Therapeutics generated -$1.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 52.2% from the prior year.
Nuo Therapeutics held $549K in cash against $0 in long-term debt as of fiscal year 2025.
Nuo Therapeutics had 48M shares outstanding in fiscal year 2025. This represents an increase of 2.9% from the prior year.
Margins & Returns
Nuo Therapeutics's gross margin was 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.9 percentage points from the prior year.
Nuo Therapeutics's operating margin was -75.9% in fiscal year 2025, reflecting core business profitability. This is up 104.1 percentage points from the prior year.
Nuo Therapeutics's net profit margin was -75.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 94.4 percentage points from the prior year.
Capital Allocation
Nuo Therapeutics invested $275K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 77.3% from the prior year.
AURX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M+18.7% | $1.1M+6.3% | $1.0M+47.4% | $700K+44.6% | $484K+22.7% | $395K+6.4% | $371K+1.7% | $365K |
| Cost of Revenue | $452K+10.8% | $408K+0.4% | $407K+155.2% | $159K+31.7% | $121K+40.1% | $86K-14.0% | $101K+53.8% | $65K |
| Gross Profit | $850K+23.4% | $688K+10.1% | $625K+15.6% | $541K+48.8% | $363K+17.8% | $308K+14.1% | $270K-9.7% | $299K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $1.3M+2.2% | $1.3M+8.8% | $1.2M-2.3% | $1.2M+7.6% | $1.1M+18.2% | $938K+10.6% | $848K+0.8% | $841K |
| Operating Income | -$446K+22.9% | -$579K-7.3% | -$540K+17.2% | -$652K+12.5% | -$745K-18.4% | -$629K-9.0% | -$577K-6.5% | -$542K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$618K-6.9% | -$578K-7.5% | -$538K+17.2% | -$650K+12.9% | -$746K-50.2% | -$497K+14.1% | -$578K-7.0% | -$540K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9M+5.4% | $1.8M-4.3% | $1.9M+41.8% | $1.4M+18.6% | $1.1M-3.6% | $1.2M-30.8% | $1.7M+21.0% | $1.4M |
| Current Assets | $1.5M+10.2% | $1.4M-5.7% | $1.5M+71.4% | $853K+41.9% | $602K-28.5% | $842K-37.3% | $1.3M+14.3% | $1.2M |
| Cash & Equivalents | $264K-51.9% | $549K+6.6% | $515K+62.7% | $316K+468.4% | $56K-80.4% | $284K-58.5% | $684K+44.6% | $473K |
| Inventory | $249K+16.3% | $214K+6.0% | $202K+21.6% | $166K+67.2% | $99K-34.1% | $150K-10.3% | $168K-22.6% | $217K |
| Accounts Receivable | $874K+55.5% | $562K-13.9% | $652K+103.5% | $320K+15.9% | $277K+11.4% | $248K-24.6% | $329K+7.9% | $305K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.3M+18.8% | $2.8M+19.4% | $2.3M+7.5% | $2.2M+60.6% | $1.4M+101.2% | $676K-18.5% | $829K+0.8% | $822K |
| Current Liabilities | $1.4M+4.8% | $1.3M+4.0% | $1.3M+25.8% | $999K-22.0% | $1.3M+121.4% | $578K-19.0% | $714K+3.4% | $690K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$1.4M-44.7% | -$957K-128.0% | -$420K+49.1% | -$825K-287.0% | -$213K-141.5% | $514K-42.3% | $890K+48.8% | $599K |
| Retained Earnings | -$35.4M-1.8% | -$34.8M-1.7% | -$34.2M-1.6% | -$33.7M-2.0% | -$33.0M-2.3% | -$32.3M-1.6% | -$31.8M-1.9% | -$31.2M |
AURX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$784K-85.6% | -$423K+40.2% | -$707K-369.3% | $262K+14276.2% | $2K+100.4% | -$491K-0.6% | -$487K+29.5% | -$691K |
| Capital Expenditures | $847-98.0% | $43K | $0-100.0% | $2K-99.3% | $230K | $0-100.0% | $151K+3579.6% | $4K |
| Free Cash Flow | -$785K-68.5% | -$466K+34.1% | -$707K-371.0% | $261K+214.3% | -$228K+53.5% | -$491K+23.2% | -$638K+8.2% | -$695K |
| Investing Cash Flow | -$847+98.0% | -$43K | $0+100.0% | -$2K+99.3% | -$230K | $0+100.0% | -$151K-3579.6% | -$4K |
| Financing Cash Flow | $500K0.0% | $500K-44.7% | $905K | $0 | $0-100.0% | $90K-89.4% | $849K+5.9% | $802K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.3%+2.5pp | 62.8%+2.2pp | 60.6%-16.6pp | 77.2%+2.2pp | 75.0%-3.1pp | 78.1%+5.2pp | 72.9%-9.2pp | 82.1% |
| Operating Margin | -34.3%+18.5pp | -52.8%-0.5pp | -52.3%+40.8pp | -93.1%+60.7pp | -153.8%+5.5pp | -159.3%-3.7pp | -155.7%-7.1pp | -148.6% |
| Net Margin | -47.5%+5.2pp | -52.7%-0.6pp | -52.1%+40.7pp | -92.8%+61.3pp | -154.0%-28.3pp | -125.8%+30.1pp | -155.9%-7.8pp | -148.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -96.7%-31.8pp | -64.9%+25.3pp | -90.2% |
| Return on Assets | -31.8%-0.5pp | -31.3%-3.4pp | -27.9%+19.9pp | -47.8%+17.3pp | -65.1%-23.3pp | -41.8%-8.1pp | -33.6%+4.4pp | -38.0% |
| Current Ratio | 1.11+0.1 | 1.06-0.1 | 1.16+0.3 | 0.85+0.4 | 0.47-1.0 | 1.45-0.4 | 1.88+0.2 | 1.70 |
| Debt-to-Equity | -2.41+0.5 | -2.93+2.7 | -5.59-2.9 | -2.65+3.7 | -6.38-7.7 | 1.32+0.4 | 0.93-0.4 | 1.37 |
| FCF Margin | -60.3%-17.8pp | -42.5%+26.0pp | -68.5%-105.7pp | 37.2%+84.3pp | -47.1%+77.1pp | -124.2%+47.9pp | -172.1%+18.5pp | -190.6% |
Note: Shareholder equity is negative (-$957K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Nuo Therapeutics's annual revenue?
Nuo Therapeutics (AURX) reported $3.3M in total revenue for fiscal year 2025. This represents a 142.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nuo Therapeutics's revenue growing?
Nuo Therapeutics (AURX) revenue grew by 142.7% year-over-year, from $1.4M to $3.3M in fiscal year 2025.
Is Nuo Therapeutics profitable?
No, Nuo Therapeutics (AURX) reported a net income of -$2.5M in fiscal year 2025, with a net profit margin of -75.8%.
What is Nuo Therapeutics's EBITDA?
Nuo Therapeutics (AURX) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nuo Therapeutics's gross margin?
Nuo Therapeutics (AURX) had a gross margin of 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nuo Therapeutics's operating margin?
Nuo Therapeutics (AURX) had an operating margin of -75.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nuo Therapeutics's net profit margin?
Nuo Therapeutics (AURX) had a net profit margin of -75.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nuo Therapeutics's free cash flow?
Nuo Therapeutics (AURX) generated -$1.1M in free cash flow during fiscal year 2025. This represents a 52.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nuo Therapeutics's operating cash flow?
Nuo Therapeutics (AURX) generated -$865K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nuo Therapeutics's total assets?
Nuo Therapeutics (AURX) had $1.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nuo Therapeutics's capital expenditures?
Nuo Therapeutics (AURX) invested $275K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Nuo Therapeutics's current ratio?
Nuo Therapeutics (AURX) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.
What is Nuo Therapeutics's debt-to-equity ratio?
Nuo Therapeutics (AURX) had a debt-to-equity ratio of -2.93 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuo Therapeutics's return on assets (ROA)?
Nuo Therapeutics (AURX) had a return on assets of -136.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nuo Therapeutics's cash runway?
Based on fiscal year 2025 data, Nuo Therapeutics (AURX) had $549K in cash against an annual operating cash burn of $865K. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nuo Therapeutics's debt-to-equity ratio negative or unusual?
Nuo Therapeutics (AURX) has negative shareholder equity of -$957K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nuo Therapeutics's Altman Z-Score?
Nuo Therapeutics (AURX) has an Altman Z-Score of -19.07, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nuo Therapeutics's Piotroski F-Score?
Nuo Therapeutics (AURX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuo Therapeutics's earnings high quality?
Nuo Therapeutics (AURX) has an earnings quality ratio of 0.34x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.